Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First results from novel anti-angiogenic drug trial in patients

20.11.2002


’Surprisingly effective’ says French research team



A new drug that targets tumour blood vessels has produced a surprisingly effective response in its first patient study - shrinking the tumours in a number of patients treated so far, according to researchers carrying out the study at the Institut Gustave Roussy in Villejuif, France.

The drug, SU011248[1], which is given in capsule form, is a signal transduction inhibitor designed to act against several abnormally behaving enzymes along the cellular signalling pathway.[2]


Results of the first Phase I study were presented today (Wednesday 20 November) at the EORTC-NCI-AACR[3] Symposium on Molecular Targets and Cancer Therapeutics, in Frankfurt.

Patients in the study had a range of advanced cancers[4], which had failed to respond to all other therapies: in many cases at least three different types of treatment had been tried.

Lead researcher Dr Eric Raymond told a news briefing: "Any activity in this situation is very promising since everything else has failed. But, we did not expect to see such a high number of responses[5] in a range of cancers."

He said that the Phase I study would continue for the next six months or so. Phase II and III studies would start immediately afterwards and would include a formal analysis of the response rate - an analysis that was inappropriate for the Phase I study, which began with very low doses of the drug.

The drug is a newcomer in the field of anti-angiogenics – drugs designed to damage tumours by attacking the network of blood vessels that ’feed’ them. Although it has been a major research field over the last decade or more, angiogenesis has not so far lived up clinically to its early research promise. But, the response in this study provides evidence that anti-angiogenics may yet have a future.

Dr Raymond said: "Initially we thought that the drug would be an angiostatic agent that stabilises tumours, rather than an angiotoxic agent that actively shrinks tumours. Angiostatic compounds were associated with a low level of response, but angiotoxics are much more promising in inducing responses. We were happily surprised right from the first patient response – a reduction of more than 50% in the tumour for six months in someone with a renal cancer that had recurred and who also had adrenal and lung secondaries that had not responded to immunotherapy."

The drug has shown activity in a range of tumours, including renal and gastro-intestinal cancers, so the researchers believe that it may be suitable for other tumour types beyond those in the Phase I study. "It seems that the drug is killing the blood vessels into tumours regardless of the tumour type," Dr Raymond said.

However, it did not appear effective against brain metastases, indicating that, like many drugs, it may not be able to pass across the blood-brain barrier.

Dr Raymond said that a lot more work needed to be done on dosing and on toxicity as the drug affected normal blood vessels as well as tumour vessels. It was also vital to get information on toxicity after repeated treatment cycles to avoid discovering late delayed cumulative side effects.

Among the side effects already seen were two unusual phenomena. The drug tanned the skin in several patients, turning it a golden colour (the drug is yellow and accumulates in the skin). But this effect wore off within a week of stopping treatment. Patients with high plasma levels of the drug suffered progressive hair discoloration. But this too was reversible. Dr Raymond said that the discoloration was likely to be due to the drug’s effect in inhibiting the MAP kinase signalling pathway and preventing the activation of a gene that triggers melanin activity.

He concluded that if the drug’s activity held up in further trials it had the potential to be a potent new weapon. "It is one of the first angiotoxic drugs with anti-tumour effects. In fact, we had too much effect in higher doses in some patients resulting in tumour necrosis that required surgery. So this drug is teaching us a lot about the potential efficacy and, just as important, about the adverse effects of new anti-angiogenic agents."


###
Notes:
[1] SU011248 is a novel orally bioavailable indolinone developed by Sugen, a California-based company that was acquired in 1999 by Pharmacia.

[2] The drug inhibits activity of the following enzymes: VEGFR (Flk-1KDR), PDGFR alpha and ß, Flt3, c-kit tyrosine kinase

[3] EORTC [European Organisation for Research and Treatment of Cancer; NCI [National Cancer Institute]; AACR [American Association for Cancer Research].

[4] Cancers included in the study were: renal, non small-cell lung, neuro-endocrine, uterine, angiosarcoma, mesothelioma, pancreatic, breast, colorectal and nasopharyngeal.

[5] Response was defined as a reduction in tumour volume of more than 50% as measured by CT scan.

Further information:
Margaret Willson (media information officer)
Tel: 44-153-677-2181
Fax: 44-153-677-2191
Mobile: 44-797-385-3347
Email:m.willson@mwcommunications.org.uk

From: 16:00hrs CET Monday 18 November to 17:00hrs CET Friday 22 November
EORTC-NCI-AACR symposium press office:
Tel: 49-697-5757-3294
Fax: 49-697-5757-3451

Margaret Willson | alfa

More articles from Health and Medicine:

nachricht Cancer cells make blood vessels drug resistant during chemotherapy
02.07.2020 | Hokkaido University

nachricht Novel potassium channel activator which acts as a potential anticonvulsant discovered
02.07.2020 | The Mount Sinai Hospital / Mount Sinai School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The lightest electromagnetic shielding material in the world

Empa researchers have succeeded in applying aerogels to microelectronics: Aerogels based on cellulose nanofibers can effectively shield electromagnetic radiation over a wide frequency range – and they are unrivalled in terms of weight.

Electric motors and electronic devices generate electromagnetic fields that sometimes have to be shielded in order not to affect neighboring electronic...

Im Focus: Gentle wall contact – the right scenario for a fusion power plant

Quasi-continuous power exhaust developed as a wall-friendly method on ASDEX Upgrade

A promising operating mode for the plasma of a future power plant has been developed at the ASDEX Upgrade fusion device at Max Planck Institute for Plasma...

Im Focus: ILA Goes Digital – Automation & Production Technology for Adaptable Aircraft Production

Live event – July 1, 2020 - 11:00 to 11:45 (CET)
"Automation in Aerospace Industry @ Fraunhofer IFAM"

The Fraunhofer Institute for Manufacturing Technology and Advanced Materials IFAM l Stade is presenting its forward-looking R&D portfolio for the first time at...

Im Focus: AI monitoring of laser welding processes - X-ray vision and eavesdropping ensure quality

With an X-ray experiment at the European Synchrotron ESRF in Grenoble (France), Empa researchers were able to demonstrate how well their real-time acoustic monitoring of laser weld seams works. With almost 90 percent reliability, they detected the formation of unwanted pores that impair the quality of weld seams. Thanks to a special evaluation method based on artificial intelligence (AI), the detection process is completed in just 70 milliseconds.

Laser welding is a process suitable for joining metals and thermoplastics. It has become particularly well established in highly automated production, for...

Im Focus: A structural light switch for magnetism

A research team from the Max Planck Institute for the Structure of Dynamics (MPSD) and the University of Oxford has managed to drive a prototypical antiferromagnet into a new magnetic state using terahertz frequency light. Their groundbreaking method produced an effect orders of magnitude larger than previously achieved, and on ultrafast time scales. The team’s work has just been published in Nature Physics.

Magnetic materials have been a mainstay in computing technology due to their ability to permanently store information in their magnetic state. Current...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

International conference QuApps shows status quo of quantum technology

02.07.2020 | Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

Aachen Machine Tool Colloquium AWK'21 will take place on June 10 and 11, 2021

07.04.2020 | Event News

 
Latest News

The lightest electromagnetic shielding material in the world

02.07.2020 | Materials Sciences

Spintronics: Faster data processing through ultrashort electric pulses

02.07.2020 | Information Technology

International conference QuApps shows status quo of quantum technology

02.07.2020 | Event News

VideoLinks
Science & Research
Overview of more VideoLinks >>>